High-impact drugs represent proportionately low utilization compared to opioids or NSAIDs, but they can increase pharmacy spend exponentially on impacted claims.
Discover what’s in store for utilization review—everything from compliance with state regulations to adapting to new care models for mental health to the promise of AI-driven processes.
Insureds want fee transparency. The right TPA partner will communicate effectively, demonstrate where there are savings and work to build tailored solutions.
CorVel has witnessed topical costs rise following the recent drop in opioid prescriptions, and now offers alternatives to manage their expense without impacting care.
Data, AI and point-of-care screening devices are revolutionizing the musculoskeletal health care field, giving providers and patients a real-time understanding of recovery and the solutions that can drive success.
Obesity has many implications for injured workers, from being a catalyst for injuries to increasing healthcare costs and lengthening time away from work.
With a plethora of technology and innovation on the horizon for workers’ compensation, it’s important to pause and review the core competencies that built this industry and how good data can be used to enhance each.
At the age of 22, Amnon Rattray experienced the most terrifying accident of his life. Today, he’s turning his catastrophic workplace injury into a story of inspiration for others.
Physician-dispensed topicals are costly and there’s no evidence that they are more effective than what is available through the more traditional distribution network of the retail pharmacy network. Why aren’t more states taking action?
In part 4 of our 2024 drug trends series, we’re evaluating workers’ comp high impact drug class patterns and strategies to address the challenges these cost drivers are creating.
Two recent One Call hires demonstrate the positive effect external talent and perspectives have on bringing forth successful workers’ compensation solutions.
In part 3 of our 2023 drug trends series, we’re evaluating workers’ comp opioid patterns and the strategies being used to continue their decline in use and manage their risks.